Clinical Trial Update: Biomarkers of Injectable Extended Release Naltrexone Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring biomarkers of injectable extended-release naltrexone in heroin and opioid dependence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heroin Dependence
• Opioid Dependence

Drugs mentioned

• injectable extended-release naltrexone (naltrexone extended-release)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heroin Dependence, Opioid Dependence | Phase 4 | Status: COMPLETED